Today I attended the seminar “The Human Brain, Development and Structure” (El Cerebro Humano, Desarrollo y Estructura) presented by Professor Emeritus Dr. Miguel Marín-Padilla (Department of Pathology, Dartmouth Medical School, Hanover NH, USA) here at Vall d’Hebron Hospital (Neuroscience Seminars). Sincerely, it was probably the most pleasant seminar of the last year. Miguel is able to teach that science is not necessarily joined to complex and expensive techniques. He encourage young researchers to use their minds and innovate. Difficult words nowadays when science has become a pseudo-industrial activity.
One thing is clear. Real skillful scientists are modest.
Dr. Manuel Comabella and Dr. Xavier Montalban from our research group have contributed to the study “Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis” published in Nature this month (Nature 476, 214–219). This is probably the largest genetics study ever undertaken on Multiple Sclerosis and includes contributions from almost 250 researchers as members of the International Multiple Sclerosis Genetics Consortium and the Wellcome Trust Case Control Consortium.
Yesterday, Dr. Ignasi Barba made an introduction to Metabonomisc in our Lab seminars. Ignasi Barba is member of the Research Group on Cardiovascular Diseases at the same institution where he is in charge of the Metabomics Unit .
Abstract of the presentation:
“Drug discovery and development are extremely time and resources consuming processes. Computational approaches offer an inexpensive and interesting approach that can expedite drug discovery, design, development and optimization of lead compounds. Commonly used computational approaches include ligand-based drug design (e.g. pharmacophore searches), structure-based drug design (docking), homology modeling and quantitative structure-activity and quantitative structure-property relationships (QSAR/QSPR). These approaches can also guide site directed mutagenesis, shed some light on protein behavior, peptide binding and molecular recognition phenomena. In this talk, several first hand examples of successful interactions between molecular modeling, molecular biology and pharmacology will be covered with the aim of improving positive interactions between experimentalists and molecular modelers. If you ever wondered what is all the fuzz about molecular modelers and how they could help your research, this talk is for you.”